Skip to main content
OpenTrials
Completed

NCT Number: NCT05948527

Safety and Efficacy of High Flow Nasal Canula in Patients With Mild Hypercapnia

Evaluate safety and efficacy of application ( high flow nasal canula) in cases with mild hypercapnia, included 30 patients who were hospitalized in Mansoura University chest department with mild Hypercapnia (Pco2 range 45-60 mmhg and power of hydrogen not less 7.30) of different pulmonary disease categories (Chronic obstructive pulmonary disease acute exacerbation, pneumonia, Interstitial lung diseases, etc).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercapnia Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Respiratory

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mansoura University Hospitals

Al Mansurah, Dakahlia Governorate, 35511, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with mild Hypercapnia

Exclusion criteria

  • Excluded cases had age less than 18 years or pediatric group .
  • patients with their mental state altered, confused, comatose, severe agitation or non cooperative
  • Cases with moderate or severe Hypercapnia
  • cases in need for immediate invasive mechanical ventilation
  • cases with respiratory rate more than 35 breath per minute.
  • cases with Respiratory exhaustion , fatigue , excess use of respiratory accessory muscles
  • Shock , hemodynamic instability, post arrest cases,
  • cases with facial trauma or severe nasal deformity,
  • Patients with sleep breathing disorders or upper airway obstruction
  • patients with history of home ventilation prior admission

Treatment and study plan

high flow nasal canula

Device

administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.

Primary outcomes

  1. Arterial Blood Gases changes

    Time frame: 48 hours

    The primary outcome was concerned about changes in Arterial Blood Gases in first 24 h after admission and the same changes 48 h after admission.

Secondary outcomes

  1. Number of participants in need for ventilation

    Time frame: 7 days

    Secondary outcome was concerned about need to non invasive mechanical ventilation or invasive mechanical ventilation.

Sponsors and collaborators

Lead sponsor

Mansoura University

Other

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jul 17, 2023
Registry last updated
Jul 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.